Email: info@neweastbio.com   |  Call: 6109452007

IDH1(R132P)

Anti-IDH1(R132P) Mouse Monoclonal Antibody
5/5

$495.00

Cat.#:  26406

   Size:   100 μl

In Stock

          Product Description          
IDH1(R132P) 
Cat. #:   26406
Gene Symbol:  IDH2; D2HGA2; ICD-M; IDH; IDHM; IDP; IDPM; mNADP-IDH
Description:   Anti-IDH1(R132P) Mouse Monoclonal Antibody
Background:   Isocitrate dehydrogenases (IDH) catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
Immunogen:   A synthetic peptide from the internal region of IDH1 which includes the mutation of R132P, human origin.
Applications:   ELISA, WB, IF, IHC
Recommended Dilutions:    ELISA: 1:1000-1:5000 WB: 1:100-1:1000 IF: 1:50-1:100 IHC: 1:50-1:100
Concentration:    1 mg/ml
Host Species:   Mouse
Format:   Liquid
Clonality:   Monoclonal
Isotype:   IgG
Purity:   Purified from ascites
Preservative:  No
Constituents:  PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity:  recognizes R132P mutant, but not wild type IDH2 of vertebrates.
Storage Conditions:   Store at -20°C. Avoid repeated freezing and thawing
Western blot:   Western blot analysis of recombinant IDH1(R132P) and wild type proteins. Purified His-tagged IDH1(R132P) (lane 1) and corresponding wild type IDH1 protein (lane 2) were blotted with Anti-IDH1(R132P) monoclonal antibody (Cat. #26406).Immunofluorescence:   Immunofluorescence of cells expressing IDH1 proteins with Anti-IDH1(R132P) antibody. HEK293T cells were transfected with pCDNA3-GFP-IDH1(R132P) plasmid, pCDNA3-GFP-IDH1 (WT) plasmid , pCDNA3-GFP-IDH1(R132S) plasmid, pCDNA3-GFP-IDH1(R132L) plasmid , pCDNA3-GFP-IDH1(R132G) plasmid or pCDNA3-GFP-IDH1(R132C) plasmid , then fixed and stained with Anti-IDH1(R132P) monoclonal antibody (Cat. #26406).
          Publications          
01. Case report: Tall cell carcinoma with reversed polarity of the breast: an additional case and review of the literature
Front Oncol. 2024  PMID: 38434689
02. The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast
Appl Immunohistochem Mol Morphol. 2022  PMID: 36222504
03. Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome
Am J Surg Pathol. 2021  PMID: 33739791
04. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies : Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome
Am J Surg Pathol. 2021  PMID: 34265800
05. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations
Surg Pathol Clin. 2021  PMID: 34373096
06. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management
Am J Surg Pathol. 2020  PMID: 31876581
07. Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity
Modern Pathology. 2020  PMID: 31896809
08. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants
Hum Pathol. 2020  PMID: 33017591
09. DNA methylation-based classification of sinonasal undifferentiated carcinoma
Modern Pathology, 2019  PMID: 31186531
10. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 R172 mutations
Mod Pathol. 2019  PMID: 30952970
11. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma
Mod Pathol. 2019  PMID: 30206411
12. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy
Cell Res. 2019  PMID: 31024166
13. Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing
J Mol Diagn. 2018  PMID: 29981867
14. Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas
Am J Surg Pathol. 2017  PMID: 28945625
15. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCMode
PLoS One. 2016  PMID: 26820720
16. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
Proc Natl Acad Sci USA. 2016  PMID: 27956631
17. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
J Neurochem. 2015  PMID: 25251602
18. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
Brain Tumor Pathol. 2015  PMID: 25324168
19. Mutant IDH inhibits HNF-4a to block hepatocyte differentiation and promote biliary cancer
Nature. 2014  PMID: 25043045